We focus on therapies for the treatment of bronchopulmonary disease
This section of the website provides information for existing and potential investors in Vectura Group plc including financial reports, an interactive share price chart and updates on our latest news.
Vectura's focused application of technology, know-how and expertise has demonstrated that the potential for new inhaled pharmaceuticals with real therapeutic and commercial value can be realised.
Annual Report and Accounts for Year Ended 31 March 2014
JP Morgan Healthcare Conference, London
Jefferies 2014 Global Healthcare Conference, New York, 3 June 2014
19 Aug 2014
Vectura Group plc - Interim Management Statement
30 Jun 2014
Vectura announces a further US collaboration agreement with a leading international pharmaceutical company for the VR506 asthma therapy
16 Oct 2014
Block Listing Return
09 Oct 2014
Approval in Portugal for AirFluSal Forspiro
Share price table
Interim Results for the six months ending 30 September 2014
Stay informed Register to our news alert and receive latest updates on news and events
For general enquiries, call us on +44 (0)1249 667700. For more specific enquiries, visit Contact us
Most computers will open PDF documents automatically, but you may need to download Adobe Reader.